The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.
To better understand the relationship between cardiovascular disease and liver disease in individuals with HIV, researchers examined both traditional risk factors and HIV-specific risk factors of the...
Researchers identified the prevalence of non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), and non-alcoholic steatohepatitis (NASH) in individuals who are overweight or obese. ...
Nonalcoholic fatty liver disease is estimated to occur in 1 in 4 adults worldwide but understanding of the disease and associated complications is lacking. The American Heart Association recently released a...
While it has proven safe and effective for treating recurrent or refractory Clostridiodes difficile infections in patients with inflammatory bowel disease, fecal microbiota transplantation may also improve...
Preliminary results of the PROMISE trial highlight the relationship between nonalcoholic fatty liver disease and cardiovascular disease, which has been debated previously.
Research has shown that nonalcoholic fatty liver disease (NAFLD) is associated with an increased risk of incident cardiovascular disease (CVD), but authors of a new study sought to determine which...
Studies have shown that fasting from dawn to sunset can improve certain conditions such as diabetes and hyperlipidemia. Authors of a new study presented at DDW investigated whether this type of fasting can...
Intrahepatic cholestasis of pregnancy is the most common liver disease unique to pregnancy. The authors of a study presented at DDW 2019 investigated its association with NAFLD in nearly 150 pregnancies. ...
Researchers evaluated the impact of weight loss surgery on nonalcoholic fatty liver disease 5 years postsurgery among more than 200 individuals with persistent disease.
